EE200200040A - Ketotifeeni sisaldav oftalmiline ravimkoostis - Google Patents

Ketotifeeni sisaldav oftalmiline ravimkoostis

Info

Publication number
EE200200040A
EE200200040A EEP200200040A EEP200200040A EE200200040A EE 200200040 A EE200200040 A EE 200200040A EE P200200040 A EEP200200040 A EE P200200040A EE P200200040 A EEP200200040 A EE P200200040A EE 200200040 A EE200200040 A EE 200200040A
Authority
EE
Estonia
Prior art keywords
pharmaceutical composition
composition containing
ophthalmic pharmaceutical
containing ketotifen
ketotifen
Prior art date
Application number
EEP200200040A
Other languages
English (en)
Inventor
Johanna Adam Marcia
Fetz Andrea
Lajos Kis Gy�rgy
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of EE200200040A publication Critical patent/EE200200040A/et
Publication of EE05439B1 publication Critical patent/EE05439B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EEP200200040A 1999-07-23 2000-07-21 Ketotifeeni sisaldav oftalmiline ravimkoostis EE05439B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99114508 1999-07-23
PCT/EP2000/007030 WO2001007049A2 (en) 1999-07-23 2000-07-21 Ophthalmic composition comprising ketotifen

Publications (2)

Publication Number Publication Date
EE200200040A true EE200200040A (et) 2003-04-15
EE05439B1 EE05439B1 (et) 2011-08-15

Family

ID=8238654

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200040A EE05439B1 (et) 1999-07-23 2000-07-21 Ketotifeeni sisaldav oftalmiline ravimkoostis

Country Status (20)

Country Link
US (2) US6777429B1 (et)
EP (1) EP1198223A2 (et)
JP (1) JP2003505419A (et)
KR (1) KR20020012261A (et)
CN (1) CN1358086A (et)
BR (2) BRPI0017528B8 (et)
CA (1) CA2377024A1 (et)
CZ (1) CZ300614B6 (et)
EE (1) EE05439B1 (et)
HK (1) HK1046631A1 (et)
HU (1) HU230738B1 (et)
IL (1) IL146973A0 (et)
MX (1) MXPA02000849A (et)
NO (1) NO331228B1 (et)
NZ (1) NZ516108A (et)
PL (1) PL202496B1 (et)
RU (1) RU2248789C2 (et)
UA (1) UA74788C2 (et)
WO (1) WO2001007049A2 (et)
ZA (1) ZA200200425B (et)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR034371A1 (es) * 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
AR034372A1 (es) * 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
WO2002100436A2 (en) * 2001-06-08 2002-12-19 Novartis Ag Ophthalmic once-a-day composition
KR20050092429A (ko) * 2003-01-22 2005-09-21 니찌방 가부시기가이샤 안질환 치료용 경피 흡수형 제제, 그 사용, 및 안질환치료약의 눈의 국소 조직으로의 이행 방법
US20070208058A1 (en) * 2004-10-25 2007-09-06 Bryant Roy W Stable Pharmaceutical Compositions and Methods of Making and Using Same
US20060089384A1 (en) * 2004-10-25 2006-04-27 Minno George E Ophthalmic compositions and methods of using the same
WO2006047418A1 (en) * 2004-10-25 2006-05-04 Alimera Sciences, Inc. Ophthalmic compositions and methods of using the same
US20070048389A1 (en) * 2005-08-26 2007-03-01 Fu-Pao Tsao Stabilized and preserved ketotifen ophthalmic compositions
US20070077302A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for stabilizing ophthalmic compositions
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
US8445437B2 (en) * 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
WO2008042454A1 (en) 2006-09-29 2008-04-10 Johnson & Johnson Vision Care, Inc. Methods and ophthalmic devices used in the treatment of ocular allergies
WO2008153761A1 (en) * 2007-05-23 2008-12-18 Mastcell Pharmaceuticals, Inc. Methods
WO2009045291A2 (en) * 2007-09-28 2009-04-09 The Brigham And Women's Hospital, Inc. Mast cell stabilizers in the treatment of obesity
WO2009142772A2 (en) * 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
JP2012520880A (ja) * 2009-03-17 2012-09-10 アーシエックス セラピューティックス， インコーポレイテッド ケトチフェンの眼科用製剤および使用方法
RU2549472C1 (ru) * 2013-12-26 2015-04-27 Илья Александрович Марков Фармацевтическая композиция в форме капель для профилактики и лечения аллергических заболеваний глаз
KR20210157427A (ko) 2015-12-03 2021-12-28 리제너론 파마슈티칼스 인코포레이티드 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN111450051B (zh) * 2020-04-21 2022-03-18 武汉贝参药业股份有限公司 一种富马酸酮替芬口服溶液的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62277323A (ja) 1986-02-19 1987-12-02 Sankyo Co Ltd フマル酸ケトチフエン含有点眼液の製法
RU2003350C1 (ru) * 1991-03-01 1993-11-30 Институт иммунологии Способ лечени глюкокортикостероидзависимых атопических заболеваний
RU2007117C1 (ru) * 1992-03-20 1994-02-15 Юлия Михайловна Залесская Способ индивидуального подбора веществ для коррекции нарушений в организме
US5624962A (en) * 1993-04-16 1997-04-29 Wakamoto Pharmaceutical Co., Ltd. Aqueous drug composition having property of reversible thermosetting gelation
JPH07324034A (ja) * 1994-05-30 1995-12-12 Toa Yakuhin Kk フマル酸ケトチフェン含有の点眼剤
JPH11189533A (ja) * 1997-12-25 1999-07-13 Taisho Pharmaceut Co Ltd 点眼薬
EP0938896A1 (en) 1998-01-15 1999-09-01 Novartis AG Autoclavable pharmaceutical compositions containing a chelating agent

Also Published As

Publication number Publication date
WO2001007049A2 (en) 2001-02-01
RU2248789C2 (ru) 2005-03-27
BRPI0017528B8 (pt) 2021-05-25
IL146973A0 (en) 2002-08-14
HUP0202243A2 (hu) 2002-12-28
BRPI0017528B1 (pt) 2017-06-13
NZ516108A (en) 2004-04-30
EP1198223A2 (en) 2002-04-24
BR0012696A (pt) 2002-04-09
EE05439B1 (et) 2011-08-15
CZ300614B6 (cs) 2009-07-01
NO20020319L (no) 2002-01-21
JP2003505419A (ja) 2003-02-12
WO2001007049A3 (en) 2001-03-29
KR20020012261A (ko) 2002-02-15
US20020183359A1 (en) 2002-12-05
NO331228B1 (no) 2011-11-07
PL202496B1 (pl) 2009-06-30
MXPA02000849A (es) 2002-07-30
PL352382A1 (en) 2003-08-25
US6774137B2 (en) 2004-08-10
BRPI0017528A2 (pt) 2010-01-19
ZA200200425B (en) 2002-10-30
UA74788C2 (en) 2006-02-15
US6777429B1 (en) 2004-08-17
CZ2002243A3 (cs) 2002-04-17
HK1046631A1 (zh) 2003-01-24
HU230738B1 (hu) 2018-01-29
CN1358086A (zh) 2002-07-10
NO20020319D0 (no) 2002-01-21
HUP0202243A3 (en) 2006-03-28
CA2377024A1 (en) 2001-02-01

Similar Documents

Publication Publication Date Title
FI991485A0 (fi) Uusi farmaseuttinen koostumus
NO20015175L (no) Farmasöytisk sammensetning
EE05439B1 (et) Ketotifeeni sisaldav oftalmiline ravimkoostis
FIU20000164U0 (fi) Uusi farmaseuttinen formulaatio
DK1052974T3 (da) Farmaceutisk sammensætning indeholdende epothilon
PT1242087E (pt) Composicoes farmaceuticas
ID27415A (id) Komposisi farmaseutik
DE60011487D1 (de) Ophthalmisches Gerät
FI20010683L (fi) Nateglinidiä sisältävä koostumus
DE60037203D1 (de) Medikamentenspender
DE60011853D1 (de) Injektionsspritze
NO20012915D0 (no) Ny farmasöytisk formulering
DK1395242T3 (da) Flydende farmaceutisk sammensætning
NO20020086D0 (no) Smaksmaskerte farmasöytiske flytende formuleringer
NO992339L (no) Farmasöytiske formuleringer
ID29262A (id) Komposisi farmasi
PT1086701E (pt) Composicao laxante contendo simeticone
ID27201A (id) Komposisi farmasi
NO20022606D0 (no) Farmasöytiske kombinasjoner
NO20015510L (no) Medikament for lokal påföring
NO20014926D0 (no) Farmasöytiske forbindelser
PT1239832E (pt) Composicoes farmaceuticas
NO20003786D0 (no) Oftalmisk sammensetning
ID30032A (id) Formulasi farmasi
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida